176 unknown. 176 Phase 2, 45 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 176 | Unknown 176 |
| Phase 1 | 45 | Unknown 45 |
| Phase 3 | 8 | Unknown 8 |
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) Metformin, Semaglutide Injectable Product - Polycystic Ovary Syndrome | Phase 2 / Phase 3 | Unknown | University of Hull | 60 | 2025-03-01 | 2024-05-10 |
| Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer RC48/Carboplatin - Ovarian Cancer | Phase 2 | Unknown | Sun Yat-sen University | 47 | 2024-09-01 | 2024-08-28 |
| An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer Statin, Sugar pill - Ovarian Cancer | Phase 2 | Unknown | Anhui Provincial Cancer Hospital | 500 | 2024-06-30 | 2024-06-21 |
| Fluzoparib Neoadjuvant Therapy for Ovarian Cancer Fluzoparib - Ovarian Cancer | Phase 2 | Unknown | Qilu Hospital of Shandong University | 48 | 2024-06-18 | 2024-11-27 |
| A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer Bevacizumab； HRS-1167 - Recurrent Ovarian Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 54 | 2024-03-15 | 2024-04-11 |
| A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer SHR-1921, carboplatin, platinum-based doublet chemotherapy - Ovarian Cancer | Phase 2 / Phase 3 | Unknown | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 520 | 2024-02-15 | 2024-01-18 |
| Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) Bevacizumab, Olaparib - Ovarian Cancer | Phase 2 | Unknown | Vall d'Hebron Institute of Oncology | 100 | 2024-02-06 | 2024-05-09 |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi Fluzoparib, Fluzoparib+Apatinib - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Unknown | Guangxi Medical University | 80 | 2023-12-10 | 2023-12-07 |
| Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors Dalpiciclib plus letrozole - Recurrent Ovarian Carcinoma | Phase 2 | Unknown | Fengzhi Feng | 30 | 2023-11-17 | 2024-02-06 |
| Hyperpolarized 13C MRI for Cancer Immunotherapy Hyperpolarized 13C-Pyruvate injection - Gynecologic Cancer, Cervical Cancer | Phase 2 | Unknown | Chang Gung Memorial Hospital | 90 | 2023-11-01 | 2023-08-30 |
| Efficacy of Bushen Huatan Decoction in the Treatment of Polycystic Ovary Syndrome Bushen Huatan Decoction, Placebo - Polycystic Ovary Syndrome | Phase 1 / Phase 2 | Unknown | Jiangxi University of Traditional Chinese Medicine | 68 | 2023-09-01 | 2023-09-08 |
| Efficacy of Jianpi Qushi Huatan Decoction in the Treatment of Polycystic Ovary Syndrome Jianpi Qushi Huatan Decoction, Placebo - Polycystic Ovary Syndrome | Phase 1 / Phase 2 | Unknown | Jiangxi University of Traditional Chinese Medicine | 68 | 2023-08-31 | 2023-09-08 |
| Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer Aribulin;carboplatin;bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 38 | 2023-08-01 | 2023-07-28 |
| A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Fluzoparib, QL1101 - Ovarian Cancer | Phase 2 | Unknown | Yongpeng Wang | 25 | 2023-07-27 | 2023-07-28 |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies ILB-2109, Toripalimab - Head and Neck Cancer, Cervical Cancer | Phase 1 / Phase 2 | Unknown | Innolake Biopharm | 200 | 2023-07-25 | 2024-05-21 |
| Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy Sodium Sulfate, Hydration, Cisplatin - Epithelial Ovarian Cancer, Acute Kidney Injury Due to Circulatory Failure | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 110 | 2023-05-01 | 2023-05-26 |
| The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab Fuzuloparib Combination with Bevacizumab - Recurrent Ovarian Cancer | Phase 2 | Unknown | Fudan University | 44 | 2023-04-30 | 2023-04-19 |
| Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor Niraparib, Dostarlimab, Bevacizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | University Health Network, Toronto | 40 | 2023-02-23 | 2024-01-17 |
| Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer Lenvatinib+Toripalimab. - Recurrent Ovarian Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 69 | 2023-02-01 | 2024-02-05 |
| Signal TrAnsduction Pathway Activity Analysis in OVarian cancER Letrozole Oral Product, Bicalutamide Oral Product, Everolimus Oral Product - Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation | Phase 2 / Phase 3 | Unknown | Gynaecologisch Oncologisch Centrum Zuid | 148 | 2023-01-31 | 2023-04-18 |
Showing 20 of 176. Sign in to see all of them.
Ovarian Neoplasms (126) · Carcinoma, Ovarian Epithelial (44) · Fallopian Tube Neoplasms (28) · Endometrial Neoplasms (14) · Polycystic Ovary Syndrome (14) · Primary Ovarian Insufficiency (12) · Uterine Cervical Neoplasms (12) · Breast Neoplasms (10) · Recurrence (9) · Neoplasms (8) · Pancreatic Neoplasms (8) · Colorectal Neoplasms (7) · Melanoma (6) · Sarcoma (5) · Stomach Neoplasms (5)
Female Urogenital Diseases (176) · Female Urogenital Diseases and Pregnancy Complications (176) · Genital Diseases (176) · Urogenital Diseases (176) · Genital Diseases, Female (174) · Endocrine System Diseases (170) · Gonadal Disorders (170) · Ovarian Diseases (169) · Neoplasms (152) · Neoplasms by Site (143) · Urogenital Neoplasms (143) · Endocrine Gland Neoplasms (142) · Genital Neoplasms, Female (142) · Neoplasms by Histologic Type (56)
Carboplatin (26) · Paclitaxel (24) · Bevacizumab (12) · apatinib (8) · olaparib (8) · Gemcitabine (7) · Cisplatin (6) · niraparib (6) · pembrolizumab (6) · Albumin-Bound Paclitaxel (5) · Etoposide (5) · Metformin (5) · Cyclophosphamide (4) · Docetaxel (4) · Drug Therapy (4)
Peking Union Medical College Hospital (6) · Yonsei University (5) · Sun Yat-sen University (4) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (3) · Herbert Irving Comprehensive Cancer Center (3) · Lei Li (3) · National Cancer Institute, Naples (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · AltaRex (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Catholic University of the Sacred Heart (2) · Center for Human Reproduction (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Jiangxi University of Traditional Chinese Medicine (2) · Loyola University (2)
China (49) · United States (35) · Italy (11) · South Korea (9) · Canada (6) · Egypt (6) · Germany (6) · United Kingdom (6) · France (5) · Spain (5) · Australia (3) · Iran (3) · Netherlands (3) · Russia (3) · Taiwan (3)
Lei Li, M.D. (3) · Amy D. Tiersten, MD (2) · Gordon J.S. Rustin, MD (2) · Hala Gabr, MD (2) · Jianwei Zhou, M.D. (2) · Sayed Bakry, PhD (2) · Xiaoxiang Chen, MD,PhD (2) · Ahmed Abdullah Elberry Elberry, MD (1) · Alain Zeimet (1) · Aldar Bourinbaiar, PhD, MD/PhD (1) · Aleksandar Ljubic, MD, PhD (1) · Ana Oaknin (1) · Andrea Jewell, MD (1)
PMID 37185961, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 14701743, PMID 14970858, PMID 15327776, PMID 15367671, PMID 15665856, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16239238, PMID 16357170, PMID 16394300, PMID 16912188, PMID 16946210, PMID 17714938, PMID 18024865, PMID 18268546, PMID 18955455, PMID 19049966, PMID 19553641, PMID 19779458, PMID 19819917, PMID 20087581, PMID 20388201, PMID 20551068, PMID 20606085, PMID 20609467, PMID 20609468, PMID 21276234, PMID 21720365, PMID 21862407, PMID 22203755, PMID 22204724, PMID 22204725, PMID 22237781, PMID 22452356, PMID 22576213, PMID 22711857
2016 (1), 2018 (1), U10CA027469 (1), U10CA180868 (1)